Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aviceda Therapeutics

News headline image
Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Completes Enrollment of Phase 2b SIGLEC Study Assessing the Safety and Efficacy of AVD-104 for Geographic Atrophy Secondary to AMD
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Announces Addition of Erin Lavelle to Board of Directors
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Announces Formation of Renowned European Clinical Advisory Board
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Announces First Patient Dosed in Part 2 of the Phase 2/3 SIGLEC Clinical Trial Assessing AVD-104 for the Treatment of Geographic Atrophy
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Announces Topline Data from Part 1 of the Phase 2/3 SIGLEC Clinical Trial for AVD-104, Demonstrating Positive Safety and Early Clinical Efficacy in Patients with Geographic Atrophy
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Announces First Patient Enrolled in Phase 2 GLYCO Clinical Trial Evaluating AVD-104 for the Treatment of Diabetic Macular Edema
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Completes Enrollment in Part 1 of the SIGLEC Phase 2/3 U.S. Clinical Trial; Initiation of Part 2 Imminent
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Announces AVD-104, a Novel Glycomimetic Nanoparticle, Demonstrates Continued Clinical Safety in the Treatment of Geographic Atrophy Secondary to Macular Degeneration
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda To Present at Major European Healthcare Conferences Highlighting AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of Geographic Atrophy from Macular Degeneration, in the Phase 2 SIGLEC Trial
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Appoints Biopharma and Business Senior Executive Patrick Johnson, PhD, to its Board of Directors
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical Trials for the Treatment of Geographic Atrophy from Macular Degeneration
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Announces Strategic Partnership with Queen’s University Belfast (QUB)
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Announces 3 Presentations about AVD-104, its Lead Glyco-mimetic Nanoparticle, As a Novel Treatment for Geographic Atrophy from Macular Degeneration, at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, April 2023
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Announces Successful Submission of an Investigational New Drug (IND) and Fast Track Designation (FTD) Application for AVD-104 for the Treatment of Geographic Atrophy Associated with Age-Related Macular Degeneration (AMD)
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Announces Successful Completion of Key IND Toxicity Milestone with Favorable Safety Profile in Non-Human Primates
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Announces Additional World-Class Members to its Clinical Advisory Board to Support its Clinical Development Strategy in Ophthalmology
From Aviceda Therapeutics
Via Business Wire
News headline image
Patrick Healy, a Senior Biopharma Executive with a Successful Track Record in Clinical Trials Development, joins Aviceda Therapeutics as Chief Operations Officer
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Announces Strategic Alliance with University of Georgia
From Aviceda Therapeutics
Via Business Wire
News headline image
Aviceda Therapeutics Announces Additional World-Class Members to its Scientific Advisory Board
From Aviceda Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.